Glaxo to Pay $3 Billion to Settle U.S. Sales, Avandia Cases

GlaxoSmithKline Plc agreed to pay $3 billion to resolve U.S. criminal and civil investigations into whether the U.K. company marketed drugs for unapproved uses and other matters, its biggest legal settlement.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.